We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
- Authors
Kaye, Stan B; Lubinski, Jan; Matulonis, Ursula; Ang, Joo Ern; Gourley, Charlie; Karlan, Beth Y; Amnon, Amit; Bell-McGuinn, Katherine M; Chen, Lee-May; Friedlander, Michael; Safra, Tamar; Vergote, Ignace; Wickens, Mark; Lowe, Elizabeth S; Carmichael, James; Kaufman, Bella
- Abstract
Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clinical efficacy in nonrandomized phase II trials in patients with ovarian cancer with BRCA1 or BRCA2 deficiency. We assessed the comparative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 4, p372
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.36.9215